Nehal Patel, MD
Retina Specialist · McAllen, TXNPI 1386762128
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,400 and has fallen 51.7% since, to $676 in 2025.
Across 173 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$658
- Genentech USA, Inc.$601
- Eyepoint US, Inc.$565
- Rxsight Inc$339
- Novartis$338
- plus $3K from 23 others
What the payments were for
- Speaking & faculty fees$280%
- Food & beverage$6,74498%
- Education$170%
- Gifts$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $1,215 |
| Alcon | 18 | $658 |
| Genentech USA, Inc. | 8 | $601 |
| Eyepoint US, Inc. | 7 | $565 |
| Rxsight Inc | 6 | $339 |
| Novartis | 12 | $338 |
| Regeneron Healthcare Solutions, Inc. | 6 | $334 |
| Apellis Pharmaceuticals, Inc. | 11 | $318 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $292 |
| Glaukos Corporation | 4 | $274 |
| Astellas Pharma US Inc | 2 | $270 |
| Biotissue Holdings Inc. | 4 | $248 |
| Bausch & Lomb Americas Inc. | 10 | $246 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $217 |
| Mallinckrodt Hospital Products Inc. | 4 | $189 |
| Carl Zeiss Meditec, Inc. | 1 | $131 |
| Sight Sciences, Inc. | 3 | $131 |
| Eyevance Pharmaceuticals LLC | 1 | $117 |
| Shire North American Group Inc | 4 | $78 |
| Oyster Point Pharma, Inc. | 4 | $65 |
| Lombart Brothers, Inc. | 1 | $60 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Harrow Eye, LLC | 1 | $35 |
| Aerie Pharmaceuticals, Inc. | 2 | $29 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Dompe US, Inc. | 1 | $19 |
| NEW World Medical,inc. | 1 | $15 |
| Ivantis, Inc | 1 | $15 |
| Alimera Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$514
- DEXYCU$358
- AcrySof IQ PanOptix$287
- DURYSTA$240
- OZURDEX$229
- ENVISTA$148
- VisuMax$131
- ACTHAR$128
- EYLEA$126
- Syfovre$125
- iDose$124
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$122
- Izervay$120
- EYLEA HD$120
- YUTIQ$118
- Tobradex ST$117
- IACCESS$117
- iStent inject W$117
- KXL System$117
- Photrexa$117
How this compares
$6,873 in reported general payments places this provider in the 70th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 439 | $224,218 |
| RhopressaNetarsudil Mesylate | 261 | $119,347 |
| CombiganBrimonidine Tartrate/Timolol | 299 | $114,777 |
| RestasisCyclosporine | 82 | $87,813 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 305 | $49,818 |
| RocklatanNetarsudil Mesylat/Latanoprost | 106 | $49,637 |
| Bromfenac Sodium | 240 | $48,472 |
| VyzultaLatanoprostene Bunod | 86 | $43,201 |
| Alphagan PBrimonidine Tartrate | 82 | $37,791 |
| Prednisolone Acetate | 838 | $36,880 |
| Travoprost | 181 | $34,093 |
| Brinzolamide | 167 | $33,409 |
| ProlensaBromfenac Sodium | 62 | $31,797 |
| XiidraLifitegrast | 30 | $31,671 |
| Latanoprost | 2,251 | $28,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $1,215 | $464,599902 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $29 | $168,985367 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $246 | $84,654130 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $292 | $31,79762 claims |
| AlconSimbrinza | $658 | $23,46091 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $65 | $20,04325 claims |
| NovartisTravatan Z | $338 | $5,61211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 108 retina specialist providers in Texas.
Other retina specialist in McAllen
- Victor GonzalezMcAllen$335K
- Courtney CrawfordBurleson$342K
- Jeremiah BrownSchertz$339K
- Judy KimDallas$256K
- Emmanuel ChangBellaire$254K
- Ting Fang SuarezBellaire$156K
- Hemang PandyaPlano$153K
- Margaret RunnerSouthlake$71K
- Moises ChicaSan Antonio$43K
- Garvin DavisHouston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.